Product category:
Microfluidics/Lab-on-a-chip systems
News Release from: Q Chip
Edited by the Laboratorytalk Editorial
Team on 04 February 2008
Ken Powell named as executive chairman
of Q Chip
Ken Powell Named as Executive Chairman of Q Chip.
Q Chip, a developer of microencapsulation, has announced the appointment of Ken Powell as executive chairman With a career spanning more than three decades as a senior researcher and manager in the pharmaceutical sector Ken Powell is widely acknowledged by the industry as one of its pioneers
This article was originally published on Laboratorytalk on 10 Jun 2004 at 8.00am (UK)
Related stories
Small, but perfectly formed
New technology of complex encapsulations and precision morphologies may be set to revolutionise pharmaceutical, cosmetic, and food products
Capsule design to improve drug bioavailability
Rational Capsule Design takes innovative approach of designing the delivery around an individual therapy or administration route, thereby addressing some limitations of current drug delivery methods
His previous positions include CEO of Arrow Therapeutics, head of antiviral research and head of biology at the Wellcome Foundation, and professor of virology and cell biology at the Wolfson Institute for Biomedical Research at University College, London.
Ken Powell has an enviable record in founding and building life science start-ups.
During his period of employment with the Wolfson Institute he helped establish Inpharmatica, now part of Galapagos, and Ark Therapeutics which listed on the London Stock Exchange's main market in March 2004.
Further reading
Safer delivery for delicate drugs
PolyQules are being hailed as having the potential to solve a wide spectrum of current drug delivery needs - from small molecules and combination products to protein, cell-therapies and vaccines
If chips are too big, put the lab in a bead
PCR reactions can now be easily taken out of the laboratory, opening up field-based applications from bacterial detection to DNA-based security tagging - and ushering in the era of the lab-in-a-bead
Powell currently serves as the head of Arrow Therapeutics, which he founded in 1998 and was acquired by Astra-Zeneca for $150 million in February 2007.
Commenting on his appointment Ken Powell said: "I have accepted the role of executive chairman of Q Chip for the simple reason I am excited by its prospects.
"It has undertaken some very exciting research, which provides the foundations for a strong pipeline of applications and products.
"The product opportunities presented by Q Chip's technology will offer cost effective solutions to some of the most pressing issues in the biotech industry.
"I am particularly delighted to have the opportunity to assist Q Chip in the development of its MicroPlant drug delivery technology and expanding the commercial reach of its unique ReaX range of easy to use, beaded molecular reagents".
"Ken Powell is associated with some of the United Kingdom's most dynamic biotech companies.
"The fact he has chosen to take on an executive chairmanship role and his ability to attract investment for a series of commercially successful pharmaceutical research based entities provides an enormous endorsement of the strategy Q Chip has been pursuing," said Mark Barry, chief executive officer of Q Chip.
"This key appointment maintains the momentum that has built up over the last three years".
In summer 2007 Q Chip successfully completed a funding round, which saw it raise in excess of £2 million from existing and new shareholders.
This investment is being used to accelerate ReaX and MicroPlant product development and commercialisation.
• Q Chip: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
